Pharmaceutical Executive Daily: New Research on Ozempic
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
Recent FDA Approval and Research
The FDA has approved Bayer’s Lynkuet, also known as elinzanetant, as the first dual neurokinin 1 and 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause.
- Lynkuet provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
- New research suggests Ozempic may reduce biological age.
- Novartis has a $12 billion merger agreement to acquire Avidity Biosciences.
The approval of Lynkuet is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
No specific quote available in the text.
Author's summary: New research on Ozempic and FDA approval of Lynkuet.